Oxurion at resistance level, reversal of trend?Oxurion is now in a bearish trend, will it be able to change?
Next report date
Report period
H1 2024
EPS estimate
—
Revenue estimate
—
−0.0224EUR
−18.97 MEUR
263.00 KEUR
7.56 B
About OXURION
Sector
CEO
Ghoson Pascal
Headquarters
Leuven
Website
Employees (FY)
19
Founded
2006
ISIN
BE0003846632
FIGI
BBG00JHVV4F2
Oxurion NV is a biopharmaceutical company, which engages in developing and commercializing medicines for the treatment of vitreo retinal diseases. It operates under JETREA brand name. The company was founded by Desire Collen in 1991 and is headquartered in Leuven, Belgium.
Oxurion still a good opportunity?With Oxurion reaching lows, is it still a good opportunity? The 17th of september there is some news coming out.
OXURION - lot's of potentialThese are my thoughts on OXUR . They are meant to give you an idea, not trading advice.
OXUR seems to have bottomed out, forming a double bottom on a large timeframe.
Over the last months it's been forming some nice patterns, that could very well break to the upside.
Today we're seeing is a litt
Oxurion important levels to keep an eye onIn this chart, we see what price is the best to buy & to sell.
Please leave your thought's, so we can discuss this chart
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 0G99 is 0.0001 EUR — it hasn't changed in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange OXURION NPV stocks are traded under the ticker 0G99.
OXURION NPV is going to release the next earnings report on Sep 30, 2024. Keep track of upcoming events with our Earnings Calendar.
0G99 stock is 0% volatile and has beta coefficient of 3.64. Check out the list of the most volatile stocks — is OXURION NPV there?
0G99 earnings for the last quarter are −0.35 EUR per share, whereas the estimation was −0.42 EUR resulting in a 16.67% surprise. The estimated earnings for the next quarter are −0.39 EUR per share. See more details about OXURION NPV earnings.
Yes, you can track OXURION NPV financials in yearly and quarterly reports right on TradingView.
0G99 stock hasn't changed in a week, the last month showed zero change in price, over the last year OXURION NPV has showed a 97.83% decrease.
0G99 net income for the last quarter is −8.35 M EUR, while the quarter before that showed −10.62 M EUR of net income which accounts for 21.43% change. Track more OXURION NPV financial stats to get the full picture.
No, 0G99 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, 0G99 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade OXURION NPV stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 29, 2024, the company has 19.00 employees. See our rating of the largest employees — is OXURION NPV on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So OXURION NPV technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating OXURION NPV stock shows the sell signal. See more of OXURION NPV technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. OXURION NPV EBITDA is −13.46 M EUR, and current EBITDA margin is −5.12 K%. See more stats in OXURION NPV financial statements.